Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 14, 2004 - Issue 12
Submit an article Journal homepage
29
Views
0
CrossRef citations to date
0
Altmetric
Review

New therapies for glaucoma: are they all up to the task?

Thomas Yorio UNT Health Science Center, Graduate School of Biomedical Sciences, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA. [email protected]
&
Adnan Dibas UNT Health Science Center, Graduate School of Biomedical Sciences, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA. [email protected]
Pages 1743-1762 | Published online: 25 Feb 2005

Bibliography

  • CLARK AF: Current trends in anti-glaucoma therapy . Emerg. Drugs (1999) 4:333–353.
  • •A general overview of glaucoma pathogenesis and therapeutic targets.
  • YABLONSKI ME: Ocular hypertension treatment study. Arch. Ophthalmol (2004) 122(7):1088–1089.
  • LESKEA MC, HEIJL A, HYMAN L, BENGTSSON B, KOMAROFF E: Factors for progressive and glaucoma treatment: the early manifest glaucoma trial. (2004) Curl: Opin. Ophthalmol 15(2):102–106.
  • FEINER L, PILTZ-SEYMOUR JR: Collaborative initial glaucoma treatment study. (2003) 14(2):106–111.
  • Primary Open-Angle Glaucoma. American Academy of Ophthalomolgy, San Francisco (1992):1–38.
  • TIELSCH JM, SOMMER A, KATZ J, ROYALL RM, QUIGLEY HA, JAVITT J: Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA (1991) 266:369–74.
  • ERNST ME, KELLY MW, HOEHNS JD et al: Prescription medication costs: a study of physician familiarity. Arch. Fam. Med. (2000) 9:1002–1007.
  • DOYLE WJ, SMITH ME TIERNEY JW: Glaucoma medical treatment-2002: Does yearly cost now equal the year? Optom. Vis. Sci. (2002) 79:489–492.
  • SAFRAN DG, NEUMAN P, SCHOEN C et al: Prescription drug coverage and seniors: how well are states closing the gap? Health Alf (2002) Web Exclusives: W253–W268.
  • DIGGORY P, FRANKS W: Medical treatment of glaucoma - a reappraisal of the risks. Br. J. Ophthalmol (1996) 80:85–90.
  • DINSLAGE S, HUEBER A, DIESTELHORST M, KRIEGLSTEIN GK: The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study. Graefes Arch. Clin. Exp. Ophthalmol (2004) 242:654–660.
  • TORIS C, YABLONSKI M, WANG Y, CAMRAS C: Aqueous humor dynamics in the aging human eye. Am. I Ophthalmol (1999) 127:407–412.
  • GABELT B, KAUFMAN P: Normal physiology. In: Uveoscleral outflow. Alm A, Weinreb R (Eds), Mosby-Wolfe, London. (1998):25–40.
  • GABELT BT, GOTTANKA J, LUTJEN -DRECOLL E, KAUFMAN PL: Aqueous humor dynamics and trabecular meshwork and anterior ciliary muscle morphologic changes with age in rhesus monkeys. Invest. Ophthalmol Vis. Sci. (2003) 44:2118–2125.
  • WEINREB RN, KHAW PT: Primary open-angle glaucoma. Lancet (2004) 363:1711–1720.
  • •Excellent overview of POAG, from pathology to treatment.
  • BRUBAKER RE SCHOFF EO, NAU CB, CARPENTER SP, CHEN K, VANDENBURGH AM: Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am. I Ophthalmol (2001) 131:19–24.
  • TORIS CB, CAMRAS CB, YABLONSKI ME: Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am. J. Ophthalmol (1999) 128:8–14.
  • LANGHAM ME, DIGGS E: P-Adrenergic responses in the eyes of rabbits, primates, and man. Exp. Eye Res. (1974) 19:281–295.
  • DAN JA, HONAVAR SG, BELYEA DA et al.: Enzymatic sclerostomy: pilot human study. Arch. Ophthalmol (2002) 120:548–553.
  • OSBORNE NN, UGARTE M, CHAO M, CHIDLOW G, BAE JH, WOOD JP et al: Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv. Ophthalmol (1999) 43:102–128.
  • HERNANDEZ MR, PENA JD: The opticnerve head in glaucomatous optic neuropathy. Arch. Ophthalmol (1997) 115:389–395.
  • FECHTNER RD, WEINREB RN: Mechanisms of optic nerve damage in primary open angle glaucoma. Surv. Ophthalmol (1994) 39:23–42.
  • RODIECK RW: The first steps in seeing. MA Sinauer Associates, Sunderland, Inc. (1999).
  • MINCKLER DS: Neural damage in glaucoma. In: The Optic Nerve in Glaucoma Varma R, Spaeth GI, Parker Kw (Eds), JB Lippincott, Philadelphia (1993):51–59.
  • BALAZSI AG, ROOTMAN J, DRANCE SM, SCHULZER M, DOUGLAS GR: The effect of age on the nerve fiber population of the human optic nerve. Am. J. Ophthalmol (1984) 97:760–766.
  • DOLMAN CL, MCCORMICK AQ, DRANCE SM: Aging of the optic nerve. Arch. Ophthalmol (1980) 98:2053–2058.
  • OGDEN TE, DUGGAN J, DANLEY K, WILCOX M, MINCKLER DS: Morphometry of nerve fiber bundle pores in the optic nerve head of the human. Exp. Eye Res. (1988) 46:559–568.
  • BLACK MM, LASEK RJ: Slowing of the rate of axonal regeneration during growth and maturation. Exp. Neurol (1979) 63:108–119.
  • QUIGLEY HA, ADDICKS EM: Regional differences in the structure of the lamina cribrosa and their relation to glaucomatous optic nerve damage. Arch. Ophthalmol (1981) 99:137–143.
  • QUIGLEY HA, ADDICKS EM, GREEN WR, MAUMENEE AE: Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch. Ophthalmol. (1981) 99:635–649.
  • PENA JD, NETLAND PA, VIDAL I, DORR DA, RASKY A, HERNANDEZ MR: Elastosis of the lamina cribrosa in glaucomatous optic neuropathy. Exp. Eye Res. (1998) 67:517–524.
  • QUIGLEY HA, HOHMAN RM, ADDICKS EM, MASSOF RW, GREEN WR: Morphologic changes in the lamina cribrosa correlated with neural loss in open-angle glaucoma. Am. I. Ophthalmol. (1983) 95:673–691.
  • SCHWARTZ B, RIESER JC, FISHBEIN SL: Fluorescein angiographic defects of the optic disc in glaucoma. Arch. Ophthalmol (1977) 95:1961–1974.
  • WILLIAMS RW, GELATT KN, GUM GG: Orthograde rapid axoplasmic transport and ultrastructural changes of the optic nerve. Part I. Normtensive and acute ocular hypertensive beagles. Glaucoma (1983) 5:117–128.
  • ANDERSON DR, HENDRICKSON A: Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve. Invest. Ophthalmol (1974) 13:771–783.
  • LEVY NS: The effects of elevated intraocular pressure on slow axonal protein flow Invest. Ophthalmol (1974) 13:691–695.
  • COLEMAN AL, QUIGLEY HA, VITALE S, DUNKELBERGER G: Displacement of the optic nerve head by acute changes in intraocular pressure in monkey eyes. Ophthalmology (1991) 98:35–40.
  • LEVY NS, CRAPPS EE, BONNEY RC: Displacement of the optic nerve head. Response to acute intraocular pressure elevation in primate eyes. Arch. Ophthalmol (1981) 99:2166–2174.
  • LEVY NS, CRAPPS EE: Displacement of optic nerve head in response to short-term intraocular pressure elevation in human eyes. Arch. Ophthalmol (1984) 102:782–786.
  • KERR JF, WYILIE AH, CURRLE AR: Apoptosis: a basic biologic phenomenon with wide-ranging complications in tissue kinetics. Br. J. Cancer (1972) 26:239–257.
  • LYNCH DR, DAWSON TM. Secondary mechanisms in neuronal trauma. Curl: Opin. Neurol (1994) 7:510–516.
  • YOLES E, SCHWARTZ M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv. Ophthalmol (1998) 42:367–372.
  • NEUFIELD AH: New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. J. Glaucoma (1998) 7:434–438.
  • MCKINNON SJ: Glaucoma, apoptosis andneuroprotection. Curr. Opin. Ophthalmol (1997) 8:28–37.
  • NICKELLS RW: Retinal ganglion cell death in glaucoma: the how, the witty and the maybe. J. Glaucoma (1996) 5:345–356.
  • LEVKOVITCH-VERBIN H, QUIGLEY HA, KERRIGAN -BAUMRIND LA, D 'ANNA SA, KERRIGAN D, PEASE ME: Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci.(2001) 42:975–982.
  • WHEELER LA, GIL DW, WOLDEMUSSIE E: Role of a2 adrenergic receptors in neuroprotection and glaucoma. Surv. Ophthalmol. (2001) 45:S290–S296.
  • ISENMANN S, KRETZ A, CELLERINO A: Molecular determinants of retinal ganglion cell development, survival, and regeneration. Frog. Retin. Eye Res. (2003) 4:483–543.
  • KOEBERLE PD, BAHR M: Growth and guidance cues for regenerating axons: where have they gone?' Neurobiol (2004) 59:162–180.
  • MILLER NR: Optic nerve protection, regeneration, and repair in the 21st century: LVIII Edward Jackson Memorial lecture. Am. J. Ophthalmol (2001) 132:811–818.
  • NORK TM, POULSEN GL, GHO NC, NICKELLS RW, VER HOEVE JN: Laser destruction of photoreceptors protects retinal ganglion cells in experimental glaucoma (abstract). Invest. Ophthalmol Vis. Sri. (1998) 39 (Suppl.):5876.
  • FISCHER D, PAVLIDIS M, THANOS S:Cataractogenic lens injury prevents traumatic ganglion cell death and promotes axonal regeneration both in vivo and in culture. Invest. Ophthalmol Vis. Li. (2000) 41:3943–3954.
  • HOFFMAN PN: Axonal damage. In: Optic Nerve in Glaucoma. Drance SM, Anderson DR (Eds), Kugler Pub., New York, NY (1995):123–134.
  • BUNGE MB, PEARSE DD: Transplantation strategies to promote repair of the injured spinal cord. I Rehab. Res. Dev (2003) 40:55–62.
  • KASHIWAGI K, OU B, NAKAMURA S, TANAKA Y, SUZUKI M, TSUKAHARA S: Increase in dephosphorylation of the heavy neurofilament subunit in the monkey chronic glaucoma model. Invest. Ophthalmol. Vis. Sci. (2003) 44:154–159.
  • SAWAGUCHI S, ABE H, FUKUCHI T, SUDA K, SHIRAKASHI M, IWATA K: Slow axonal transport in primate experimental glaucoma. Nippon Ganka Gakkai Zasshi [Japanese] (1996) 100:132–138.
  • CUI Q, CHO KS, SO KF, YIP HK: Synergistic effect of Nogo-neutralizing antibody IN-1 and ciliary neurotrophic factor on axonal regeneration in adult rodent visual systems. Neurotmurna. (2004) 21:617–625.
  • JO SA, WANG E, BENOWITZ LI: Ciliary neurotrophic factor is and axogenesis factor for retinal ganglion cells. Neuroscience (1999) 89:579–591.
  • CUI Q, YIP HK, ZHAO RC, SO KF, HARVEY AR: Intraocular elevation of cyclic AMP potentiates ciliary neurotrophic factor-induced regeneration of adult rat retinal ganglion cell axons. Ma. Cell. Neurosci. (2003) 22:49–61.
  • CUI Q, LU Q, SO KF, YIP HK: CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters. Invest. Ophthalmol Vis. Li. (1999) 40:760–766.
  • GINZBURG I, RYBAK S, KIMHI Y, LITTAUER UZ: Biphasic regulation by dibutyryl cyclic AMP of tubulin and actin mRNA levels in neuroblastoma cells. Proc. Natl. Acad. Sri. USA (1983) 80:4243–4237.
  • AZHDERIAN EM, HEFNER D, LIN CH, KACZMAREK LK, FORSCHER P: Cyclic AMP modulates fast axonal transport in Aplysia bag cell neurons by increasing the probability of single organelle movement. Neuron. (1994) 12:1223–1233.
  • CARLSEN RC: Axonal transport of adenylate cyclase activity in normal and axotomized frog sciatic nerve. Brain Res. (1982) 232:413–424.
  • LEON S, YIN Y, NGUYEN J, IRWIN N, BENOWITZ LI: Lens injury stimulates axon regeneration in the mature rat optic nerve. .1 Neurosci. (2000) 20:4615–4626.
  • TAYLOR JS, BAMPTON ET: Factors secreted by Schwann cells stimulate the regeneration of neonatal retinal ganglion cells. J. Anat. (2004) 204:25–31.
  • GOODRUN JF, BROWN JC, FOWLER KA, BOULDIN TW: Axonal regeneration, but not myelination is partially dependent on local cholesterol reutilization in regenerating nerve. Neuropathol Exp. Neurol (2000) 59:1002–1010.
  • BIOT LZ: Prostaglandin postscript: a personal reflection (2002). Surv. Ophthalinol 47:5231–5236.
  • GABELT BT, KAUFMAN PL: Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. (1989) 49:389–402.
  • WEINREB RN, TORTS CB, GABELT BT, LINDSEY JD, KAUFMAN PL: Effects of prostaglandins on the aqueous humor outflow pathways. Surv. Ophthalinol (2002) 47:553–64.
  • WEINREB RN, KASHIWAGI K, KASHIWAGI F, TSUKAHARA S, LINDSEY JD: Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalinol Ur. Sri. (1997) 38:2772–2780.
  • •Good demonstration of how PGs enhance uveosderal outflow.
  • CAMRAS CB: The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology (1996) 103:138–147.
  • KRAUSS AHP, WOODWARD DF: Update on the mechanism of action of Bimatoprost: A review and discussion of new evidence. Surv. Ophthalinol (2004) 49:55–511
  • •Controversy discussed regarding bimatoprost receptor specificity.
  • BRUBAKER RF: Mechanism of action of bimatoprost (Lumigun): Surv. Ophthalinol (2001) 45:5347–5351.
  • TAKAGI Y, NAKAJIMA T, SHIMAZAKI A et al.: Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp. Eye Res. (2004) 78:767–776.
  • JUMBLATT J E, JUMBLATT MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp. Eye Res. (1998) 67:341–346.
  • PINTOR J, PERAL A, NAVAS B, PELAEZ T, GALLAR J: Effects of ATP and adenine nucleotides on intraocular pressure in New Zealand rabbits (Abstract). Invest. Ophthalinol 1/is. Sci. (2000) 71:5255.
  • MITCHELL CH, CARRE DA, MCGLINN AM, STONE RA, CIVAN MM: A release mechanism for stored ATP in ocular ciliary epithelial cells. Proc Natl Acad Sci. (1998) USA 95:7174–7178.
  • PINTOR J, PELAEZ T, PERAL A: Adenosine tretraphosphate, Ap4, a physiological regulator of intraocular pressure in normotensive rabbit eyes. Pharinacol Exp. Ther. (2004) 308:468–473.
  • BRAUNAGL SC, XIAO JG, CHIOU GC: The potential role of adenosine in regulating blood flow in the eye. J. Ocul Pharinacol (1998) 14:61–73.
  • BELARDINELLI L, LINDEN J, BERNE RM: The cardiac effects of adenosine. Frog. Cardiovasc. Dis. (1989) 32:73–97.
  • LARSEN AK, OSBORNE NN: The involvement of adenosine on refinal ischemia: studies on rat. Invest. Ophthalinol Vis. Sri. (1996) 37:2603–2611.
  • MITCHELL CH, PETERSON -YANTORNOK, CARRE DA et at. A3 adenosine receptors regulate CL channels of non-pigmented ciliary epithelial cells. Ain. Physiol (1999) 276:C659–666.
  • AVILLA MY, STONE RA, CIVAN MM: Kockout of A3 adenosine receptors reduces mouse intraocular pressure. Invest. Ophthal 1/is. Sri. (2002) 43:3021–3026.
  • •First direct link of A3 adenosine receptor to IOR
  • OKAMURA T, KUROGI Y, HASHIMOTO K et at. Structure-activity relationship of adenosine A3 receptor ligands: New potential therapy for the treatment of glaucoma. Bioorg. Med. Chem. Lett. (2004) 14:3775–3779.
  • KONNO T, OHNUMA S-Y, VEMOTO K et at. Effects of 2-alkynyladenosine derivatives on intraocular pressure in rabbits. Eur. Pharmacol (2004) 486:307–316.
  • CROSSON CE: Intraocular pressure responses to the adenosine agonist cyclohexyladenosine:evidence for a dual mechanism of action. Invest. Ophthalmol 1/is. Sci. (2001) 42:1837–1840.
  • CROSSON CE, NIAZI Z: Ocular effects associated with the chronic administration of the adenosine A1 agonist cyclohexyladenosine. Curr. Eye Res. (2000) 21:808–813.
  • SHEARER TW, CROSSON CE: Adenosine A1 receptor modulation of MMP-2 by trabecular meshwork cells. Invest. Ophthalmol 1/is. ScL (2002) 43:3016–3020.
  • HELPER RS, FRANK IM: Marihuana smoking and intraocular pressure. JAMA (1971) 217:1392.
  • •Early report demonstrating TOP lowering effect of cannabinoids.
  • MERRITT JC, PERRY DD, RUSSELL DN, JONES BF: Topical A9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J. Clin. Pharmacol (1981) 21:471S–476S.
  • COOLER P, GREGG JM: The effect of A9-tetrahydrocannabinol on intraocular pressure in humans. South. Med. J. (1977) 70:951–954.
  • GREEN K, WYNN H, BOWMAN KA: A comparison of topical cannabinoids on intraocular pressure. Exp. Eye Res. (1978) 27:239–246.
  • DEVANE WA, DYSARZ IFA, JOHNSON MR, MELVIN LS, HOWLETT AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol (1988) 34:605–613.
  • DEVANE WA, HANUS L, BREUER A et at. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946–1949.
  • SUGIURA T, KONDO S, SUKAGAWA A, et al. 1-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215:89–97.
  • STRAIKER AJ, MAGUIRE G, MACKIE K, LINDSEY J: Localization of the cannabinoid CB1 receptors in human anterior eye and retina. Invest. Ophthalmol 1/is. Sci. (1999) 40:2442–2448.
  • MATSUDA S, KANEMITSU N, NAKAMURA A et al. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Exp. Eye Res. (1997) 64:707–711.
  • POCELLA A, CASELLAS P, GESSA GL, PANT L: Cannabinoid receptor CBI mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Mol. Bran] Res. (1998) 58:240–245.
  • POCELLA A, MAXIA C, GESSA GL, PANT L: The human eye expresses high levels of CB1 cannabinoid receptor mRNA. Eur. I Neurosci (2000) 12:123–127.
  • HOWLETT AC, CHAMION TM, WILKEN GH, MECHOULAM R: Sterochemical effects of 11 OH D 8 tetrahydrocannabinol-dimethyl-heptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology (1990) 29:161–165.
  • ESHHAR N, STRIEM S, BIEGON A: HU-211, a non-psychotropic cannabinoid, rescues cortical neurons from excitatory amino acid toxicity in culture. Neuroreport (1993) 5:237–240.
  • LAINE K, JARVINEN K, JARVINEN T: Topically administered CB2-receptor agonist, JWH- 133, does not decrease intraocular pressure (TOP) in normotensive rabbits. Life Sci. (2003) 72:837–842.
  • •Evidence that demonstrates only the CB1 receptor activation is involved in the TOP lowering effect of cannabinoids.
  • JARVINEN T, PATE DW, LAINE K: Cannabinoids in the treatment of glaucoma. Pharmacol. Ther. (2002) 95:203–220.
  • VORWERK CK, LIPTON SA, ZURAKOWSKI D, HYMAN BT, SABEL BA, DREYER EB, Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest. Ophthalmol. 1/is. Sci. (1996) 37:1618–1624.
  • •Early report demonstrating the neuroprotective actions of memantine.
  • OTORI Y, WET Y, BARNSTABLE CJ: Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest. Ophthalmol. 1/is. Sci. (1998) 39:972–981.
  • LAM TT, ABLER AS, KWNG JM, TSO MO: N-methyl-D-aspartate (NMDA) - induced apoptosis in rat retina. Invest. Ophthalmol 1/is. Sci. (1999) 40:2391–2397.
  • KWONG JM, LAM TT: N-methyl-D-aspartate (NMDA) - induced apoptosis in adult rabbit retinas. Exp. Eye Res. (2000) 71:437–444.
  • DREYER EB, ZURAKOWSKI D, SCHUMER RA, POD OS SM, LIPTON SA: Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Opthalmoi (1996) 114:299–305.
  • CARTER-DAWSON L, CRAWFORD ML, HARWETH RS et al.: Vitreal glutamate concentration in monkeys with experimental glaucoma. Invest . Ophthalmol. 1/is. Sri. (2002) 43:2633–2637.
  • LIPTON S A: Possible role for memantine in protecting retinal ganglion cell from glaucomatous damage. Surv. Ophthalmol. (2003) 48:538–546.
  • •Good overview of the action of memantine.
  • ADIS R & D Profile: Dexunabinol. Dexaunabinone, HU211, PA50211, PR5211007, Sinnabidol. Drugs (2003) 4:185–187.
  • DYKA F M, MAY C A, ENZ R: Metabotropic glutamate receptors are differentially regulated under elevated intraocular pressure. .1 Neurochem. (2004) 90:190–202.
  • PIN JP, DUVOISIN R: Neurotransmitter receptors. The metabotropic glutamate receptors: structure and functions. Neuropharmacology (1995) 34:1–26.
  • PAP M, COOPER GM: Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway../. Biol. Chem. (1998) 273:19929–19932.
  • BIJUR GN, DE SARNO P, JOPE RS: Glycogen synthase kinase-313 facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J. Biol. Chem. (2000) 275:7583–7590.
  • CROSS DA, CULBERT AA, CHALMERS KA, FACCI L, SKAPER SD, REITH AD: Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death. J. Neurochem. (2001) 77:94–102.
  • HUANG X, WU DY, CHEN G, MANJI H, CHEN DF: Support of retinal ganglion cell survival and axon regeneration by lithium through a Bc1-2-dependent mechanism. Invest. Ophthalmol. 1/is. Sri. (2003) 44:347–54.
  • TATTON W, CHEN D, CHALMERS -REDMAN R, WHEELER L, NIXON R, TATTON N: Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by a2-adrenergic receptor activation. Surv. Ophthalmol. (2003) 48:S25–37.
  • •Summary of a2 receptor agonists as a neuroprotection.
  • MARTINEZ A, CASTRO A, DORRONSORO I, ALONSO M: Glycogen synthase kinase-3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev (2002) 22:373–84.
  • LECLERC S, GARNIER M, HOESSEL R et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?I Biol. Chem. (2001) 276:251–60.
  • INOUE A, YANAGISAWA M, KIMURA S et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Nati Acad. Li. USA (1989) 86:2863–2867.
  • ARAI H, HORT S, ARAMORI I, OHKUBO H, NAKANISHI S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1990) 348:730–732.
  • SAKURAI T, YANAGISAWA M, TAKUWA Y et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (1990) 348:732–735.
  • BAX WA, SAXENA PR: The current endothelin receptor classification: time for reconsideration? Trends Pharmacol. Li. (1994) 15:379–386.
  • FLAMMER J, PACHE M, RESINK T: Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog. Retin. Eye Res. (2001) 20:319–349.
  • CELLINI M, POSSATI GL, PROFAZIO V, SBROCCA M, CARAMAZZA N, CARAMAZZA R: Color Doppler imaging and plasma levels of endothelin-1 in low-tension glaucoma Acta Ophthalmol. Land Suppl. (1997) 224:11–13.
  • NOSKE W, HENSEN J, WIEDERHOLT M: Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract. Craefes Arch. Clin. Exp. Ophthalmol. (1997) 235:551–552.
  • PRASANNA G, HULET C, DESAI D et al.: Effect of elevated pressure on endothelin-1 in a rat model of glaucoma. Pharmacological Res. (2005) 51:41–50.
  • •First demonstration oft elevation of pressure in rat increases aqueous ET levels.
  • THAN OS S, NASKAR R: Correlation between retinal ganglion cell death and chronically developing inherited glaucoma in a new rat mutant. Exp . Eye Res. (2004) 79:119–129.
  • KALLBERG ME, BROOKS DE, GARCIA-SANCHEZ GA, KOMAROMY AM, SZABO NJ, TIAN L: Endothelin 1 levels in the aqueous humor of dogs with glaucoma. J. Glaucoma (2002) 11:105–109.
  • LEVIN LA: Retinal ganglion cells and neuroprotection for glaucoma. Surv. Ophthalmol (2003) 48:S21–S24.
  • CIOFFI GA, ORGUL S, ONDA E, BACON DR, VAN BUSKIRK EM: An in vivo model of chronic optic nerve ischemia: the dose-dependent effects of endothelin-1 on the optic nerve microvasculature. Curr. Eye Res. (1995) 14:1147–53.
  • ORGUL S, CIOFFI GA, BACON DR, VAN BUSKIRK EM: An endothelin-1-induced model of chronic optic nerve ischemia in rhesus monkeys. Glaucoma (1996) 5:135–138.
  • STOKELY ME, BRADY ST, YORIO T: Effects of endothelin-1 on components of anterograde axonal transport in optic nerve. Invest. Ophthalmol 1/is. Sci. (2002) 43:3223–3230.
  • •Demonstrates ETs inhibitory effect on axonal transport.
  • CIOFFI GA, SULLIVAN P: The effect of chronic ischemia on the primate optic nerve. Eur. Ophthalmol (1999) 9:S34–S36.
  • BENZ D, CADET P, MANTIONE K, ZHU W, STEFANO G: Tonal nitric oxide and health: anti-bacterial and -viral actions and implications for HIV. Med. ScL Monitor (2002) 8:RA27-RA31.
  • LUTH HJ, MUNCH G, ARENDT T: Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res. (2002) 953:135–143.
  • HORI K, BURD PR, FURUKE K, KUTZA J, WEIH KA, CLOUSE KA: Human immunodeficiency virus-1-infected macrophages induce inducible nitric oxide synthase and nitric oxide (NO) production in astrocytes: astrocytic NO as a possible mediator of neural damage in acquired immunodeficiency syndrome. Blood (1999) 93: 1843-1850.
  • DEL ZOPPO G, GINIS I, HALLENBECK JM, IADECOLA C, WANG X, FEUERSTEIN GZ: Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol (2000) 10:95–112.
  • LIU B, NEUFELD AH: Nitric oxide synthase-2 in human optic nerve head astrocytes induced by elevated pressure in vitro. Arch. Ophthalmol (2001) 119:240–245.
  • •Early demonstration of an association of TOP elevation and NOS.
  • LIU B, NEUFELD AH: Expression of nitric oxide synthase-2 (NOS-2) in reactive astrocytes of the human glaucomatous optic nerve head. Glia (2000) 30:178–186.
  • SARDON T, BALTRONS MA, GARCIA A: Nitric oxide-dependent and independent down-regulation of NO-sensitive guanylyl cyclase in neural cells. Toxicol Lett. (2004) 149:75–83.
  • GARBERS DL: The guanylyl cyclase receptors. Methods (1999) 19:477–484.
  • HALLEGUA DS, WEISMAN MH: Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann. Rheum. Dis. (2002) 61:960–967.
  • JIANG X, WANG X: Cytochrome C-mediated apoptosis. Ann. Rev Biochem (2004) 73:87–106.
  • KAUSHIK S, PANDAV SS, RAM J: Neuroprotection in glaucoma. J. Postgrad. Med. (2003) 49:90–95.
  • KENT AR, NUSSDORF JD, DAVID R, TYSON F, SMALL D, FELLOWS D: Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology (2001) 108:784–787.
  • BIENZ M, CLEVERS H: Linking colorectal cancer to Wnt signaling. Cell (2000) 103:311–320.
  • KIM YM, CHUNG HT, KIM SS et al: Nitric oxide protects PC12 cells from serum deprivation-induced apoptosis by cGMP-dependent inhibition of caspase signaling. Neurosci. (1999) 19:6740–6747.
  • TAKUMA K, PHUAGPHONG P, LEE E, MORI K, BABA A, MATSUDA T: Anti-apoptotic effect of cGMP in cultured astrocytes: inhibition by cGMP-dependent protein kinase of mitochondrial permeable transition pore. J. Biol. Chem. (2001) 276:48093–48099.
  • WILLMOTT NJ, WONG K, STRONG AJ: A fundamental role for the nitric oxide-G-kinase signaling pathway in mediating intercellular Ca2' waves in glia. Neurosci . (2000) 20:1767–1779.
  • MORRISON JC, JIA L, JOHNSON EC, CEPURNA WO, SHEPARD AR, CLARK AF: Inducible nitric oide synthase (iNOS) in rat glaucoma model with chronic elevated intraocular pressure resulting from aqueous humor outflow obstruction. Invest. Ophthalmol. 1/is. Sci. (2003) 44:E-Abstract 2101.
  • •Report of controversy on correlation of elevated TOP and iNOS.
  • ULLIAN EM, BARKIS WB, CHEN S, DIAMOND JS, BARRES BA: Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Mol. Cell. Neurosci. (2004) 26:544–557.
  • •Report of controversy on RGC death by glutamate.

Websites

  • www.neimih.govieyedatai Vision Problems in the US (2002) Prevent Blindness America; National Eye Institute.
  • •A great source of data on age-related vision problems in the US.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.